Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active pharmaceutical ingredients (APIs) and critical GMP intermediates, has announced the acquisition of Actylis Eugene, the legacy Cascade Chemistry site in Eugene, Oregon.

 

The acquisition expands Agno’s US manufacturing footprint and reinforces the company’s commitment to providing onshore pharmaceutical manufacturing solutions.

 

The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility. The site is equipped with state-of-the-art GMP infrastructure capable of supporting early-phase to late-phase clinical API production. 

 

Under Actylis, the site received significant investments to expand and upgrade GMP operations, establishing a robust platform for future growth.

 

“We would like to thank Actylis for its investments and stewardship of the Eugene site, and we are extremely excited to welcome the Eugene team into the Agno Pharma platform,” said James Chen, Chief Executive Officer of Agno Pharma. 

 

“This acquisition is a transformative step forward in building a differentiated development and manufacturing hub. The Eugene site brings technical depth in early-phase API development and its high-quality GMP infrastructure will be a powerful driver of new business as we support innovative biotech and pharmaceutical partners developing novel chemical entities.”

 

Agno Pharma already serves a global client base, supplying critical GMP intermediates and APIs, drug product and implant formulation services, and analytical services from preclinical through commercial phases.